As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing
Phase I study in Lenexa, KS, of novel vaccine targeting TB virulence and latency
24-Aug-2012 -
Aeras and the Infectious Disease Research Institute (IDRI) announced the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult ...
tuberculosis
vaccines